Sugi Predict

Sugi Predict / Compounds / SCHEMBL5548828

SCHEMBL5548828

SCHEMBL5548828

COC(=O)c1cc(C)c([N+](=O)[O-])cc1C(=O)OC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRB P09619 1/20 0.60
▸ FGFR1 P11362 1/20 0.60
▸ PDGFRA P16234 1/20 0.60
▸ FLT1 P17948 1/20 0.60
▸ FGFR3 P22607 1/20 0.60
▸ KDR P35968 1/20 0.60
▸ ALDH1A1 P00352 5/20 0.46
▸ PKM P14618 2/20 0.46
▸ TDP1 Q9NUW8 2/20 0.46
▸ SIRT6 Q8N6T7 1/20 0.46
▸ SMN1; SMN2 Q16637 5/20 0.46
▸ LMNA P02545 4/20 0.46
▸ HPGD P15428 3/20 0.46
▸ HSP90AA1 P07900 2/20 0.46
▸ GALR2 O43603 1/20 0.46
▸ MITF O75030 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ XBP1 P17861 1/20 0.46
▸ CCR6 P51684 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29368901 1.00 PDGFRB (0.60) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL27603247 0.94 PDGFRB (0.55) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL273449 0.91 PDGFRB (0.62) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL4097915 0.91 PDGFRB (0.55) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL5970689 0.88 PDGFRB (0.56) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL19389743 0.88 PDGFRB (0.52) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL2897709 0.88 PDGFRB (0.67) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL25935163 0.87 PDGFRB (0.51) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL12190692 0.87 PDGFRB (0.51) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL1770763 0.87 PDGFRB (0.55) PDGFRBFGFR1PDGFRAFLT1FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129088-A1 CEREBLON E3 UBIQUITIN LIGASE INHIBITOR GAN & LEE PHARMACEUTICALS CO., LTD. (CN) 2025-04-24 — — US disclosed
EP-4471033-A1 CEREBLON E3 UBIQUITIN LIGASE INHIBITOR Gan & Lee Pharmaceuticals Co., Ltd. (CN) 2024-12-04 — — EP disclosed
CN-118632848-A Cerebellar protein E3 ubiquitin ligase inhibitors 甘李药业股份有限公司 2024-09-10 — — CN disclosed
EP-3628045-B1 COMPOUNDS UNIV SHEFFIELD (GB) 2024-07-03 — — EP disclosed
EP-3426246-B1 THIAZOLIDINONE COMPOUNDS AND USE THEREOF NATIONAL HEALTH RES INST (TW) 2024-05-01 — — EP disclosed
WO-2023143589-A1 CEREBLON E3 UBIQUITIN LIGASE INHIBITOR 甘李药业股份有限公司 2023-08-03 — — WO disclosed
CN-108883099-B Thiazolidinone compounds and use thereof 石全 2021-09-28 — — CN disclosed
US-20210113534-A1 COMPOUNDS THE UNIVERSITY OF SHEFFIELD (GB) 2021-04-22 — — US disclosed
CN-110891951-A Compound (I) 谢菲尔德大学 2020-03-17 — — CN disclosed
US-10544113-B2 Thiazolidinone compounds and use thereof NATIONAL HEALTH RESEARCH INSTITUTE (TW) 2020-01-28 — — US disclosed
US-7807670-B2 Inhibitors of papilloma virus BOEHRINGER INGELHEIM CANADA LTD. (CA) 2010-10-05 — — US disclosed
US-7807670-B2 Inhibitors of papilloma virus BOEHRINGER INGELHEIM CANADA LTD. (CA) 2010-10-05 — — US disclosed
US-20100041649-A1 INHIBITORS OF PAPILLOMA VIRUS YOAKIM CHRISTIANE 2010-02-18 — — US disclosed
US-20100041649-A1 INHIBITORS OF PAPILLOMA VIRUS YOAKIM CHRISTIANE 2010-02-18 — — US disclosed
US-7528167-B2 Inhibitors of papilloma virus BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2009-05-05 — — US disclosed
US-7528167-B2 Inhibitors of papilloma virus BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2009-05-05 — — US disclosed
CN-100453546-C Indolecarboxylic ester trimer and electrochemical cell using the same IHARA CHEMICAL IND CO (JP) 2009-01-21 — — CN disclosed
US-7255779-B2 High electromotive force and capacity as an electrochemical cell using proton as an electric charge carrier IHARA CHEMICAL INDUSTRY CO., LTD. (JP) 2007-08-14 — — US disclosed
CN-1660853-A Indolecarboxylic ester trimer and electrochemical cell using the same IHARA CHEMICAL IND CO (JP) 2005-08-31 — — CN disclosed
US-20050185247-A1 Indolecarboxylic ester trimer and electrochemical cell using the same NEC TOKIN CORPORATION (JP) 2005-08-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129088-A1 CEREBLON E3 UBIQUITIN LIGASE INHIBITOR CRBN, UBE3A, UBE3C PDGFRB 2605/4885FGFR1 4065/4885PDGFRA 3507/4885
US-10544113-B2 Thiazolidinone compounds and use thereof OPRL1, OPRD1, OPRK1 PDGFRB 1038/4885FGFR1 612/4885PDGFRA 1273/4885
US-20210113534-A1 COMPOUNDS MRGPRX2, MC2R, ADM2 PDGFRB 1653/4885FGFR1 1417/4885PDGFRA 2076/4885
US-20100041649-A1 INHIBITORS OF PAPILLOMA VIRUS REV1, CDKN1A, RB1 PDGFRB 1426/4885FGFR1 1471/4885PDGFRA 1299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.